New Approaches to Measuring Value in Oncology Therapy

home / publications / supplement / a386_12nov_oncology

eAppendix -- New Approaches to Measuring Value in Oncology Therapy

November 30th 2012

ArticleARTICLES

Appendix B -- Value of Survival Gains in Chronic Myeloid Leukemia

November 30th 2012

ArticleARTICLES

Appendix A -- Value of Survival Gains in Chronic Myeloid Leukemia

November 30th 2012

ArticleARTICLES

Participating Faculty: New Approaches to Measuring Value in Oncology Therapy

November 30th 2012

ArticleAUTHOR INDEX

Coverage and Use of Cancer Therapies in the Treatment of Chronic Myeloid Leukemia

Theodore Darkow, PharmD;J. Ross Maclean, MD;Geoffrey F. Joyce, PhD;Dana Goldman, PhD;Darius N. Lakdawalla, PhD

November 30th 2012

ArticleARTICLES

Dynamic Cost-Effectiveness of Oncology Drugs

Yang Lu, PhD;John R. Penrod, PhD;Neeraj Sood, PhD;Saarah Woodby, BA;Tomas Philipson, PhD

November 30th 2012

ArticleARTICLES

The Option Value of Innovative Treatments in the Context of Chronic Myeloid Leukemia

Yuri Sanchez, PhD;John R. Penrod, PhD;Xiaoli Lily Qiu, PhD;John Romley, PhD;Julia Thornton Snider, PhD;Tomas Philipson, PhD

November 30th 2012

ArticleARTICLES

Value of Survival Gains in Chronic Myeloid Leukemia

Wesley Yin, PhD;John R. Penrod, PhD;J. Ross Maclean, MD;Darius N. Lakdawalla, PhD;Tomas Philipson, PhD

November 30th 2012

ArticleARTICLES

Although clinical trial data have quantified patient survival gains associated with tyrosine kinase inhibitors in chronic myeloid leukemia, the overall value of these benefits is unknown.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions